Back

The combination of EWSR1-FLI1 and loss of one EWSR1 allele leads to the induction of trisomy 8

Hapugaswatta, H.; Parrales, A.; Park, H.; Kim, H.; Iwakuma, T.; Azuma, M.

2026-05-24 cancer biology
10.64898/2026.05.21.726567 bioRxiv
Show abstract

Ewing sarcoma is a pediatric cancer that develops in skeletal elements. The majority of Ewing sarcoma patients carry the aberrant EWSR1-FLI1 fusion gene. Despite trisomy 8 being an additional common aberration associated with a poor prognosis for patients, its induction mechanism remains unknown. When the EWSR1-FLI1 gene is formed, the cell loses one wildtype EWSR1 allele. To elucidate the induction mechanism of trisomy 8, we generated a cell line that allows for the conditional induction of EWSR1-FLI1 expression and EWSR1 knockdown (derived from a single EWSR1 allele. Specifically, the conditional cell line was generated by integrating the Tet-on EWSR1-FLI1 construct into the AAVS locus and adding a miniAID tag at the 5 end of the EWSR1 locus using auxin-degron system. A combination of the EWSR1-FLI1 expression and degradation of one allele-derived EWSR1 induced a high incidence of trisomy 8 within eight days, enhancing colony formation. Mechanistically, trisomy 8 is induced by the haploinsufficiency of EWSR1, and the remaining EWSR1 proteins are likely inhibited by interaction with EWSR1-FLI1. Our data showed that the knockout of EWSR1 alone was sufficient to increase the incidence of trisomy 8. Expression of wild-type EWSR1 in EWSR1 knockout cells rescued the high incidence of trisomy 8. In contrast, the EWSR1:R565A mutant, which lacks the ability to interact with Aurora B kinase, failed to rescue this phenotype. We propose that the combination of EWSR1-FLI1 expression and loss of EWSR1 contributes to the induction of trisomy 8 through the compromised EWSR1-Aurora B pathway. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=135 SRC="FIGDIR/small/726567v1_ufig1.gif" ALT="Figure 1"> View larger version (28K): org.highwire.dtl.DTLVardef@999891org.highwire.dtl.DTLVardef@1ef6748org.highwire.dtl.DTLVardef@65e475org.highwire.dtl.DTLVardef@179da40_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Cancers
200 papers in training set
Top 0.1%
23.5%
2
eLife
5422 papers in training set
Top 2%
15.0%
3
Scientific Reports
3102 papers in training set
Top 25%
4.5%
4
Frontiers in Oncology
95 papers in training set
Top 2%
2.5%
5
PLOS ONE
4510 papers in training set
Top 45%
2.5%
6
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 3%
2.5%
50% of probability mass above
7
Cell Death Discovery
51 papers in training set
Top 0.3%
2.2%
8
iScience
1063 papers in training set
Top 9%
2.2%
9
Cells
232 papers in training set
Top 1%
2.2%
10
Cell Reports
1338 papers in training set
Top 20%
2.2%
11
Oncogene
76 papers in training set
Top 0.8%
2.0%
12
Oncotarget
15 papers in training set
Top 0.1%
2.0%
13
Disease Models & Mechanisms
119 papers in training set
Top 1.0%
1.8%
14
PLOS Computational Biology
1633 papers in training set
Top 15%
1.8%
15
International Journal of Molecular Sciences
453 papers in training set
Top 7%
1.7%
16
Nature Communications
4913 papers in training set
Top 56%
1.3%
17
PeerJ
261 papers in training set
Top 11%
1.0%
18
Molecular Cancer Research
42 papers in training set
Top 0.5%
1.0%
19
Biochemistry and Biophysics Reports
28 papers in training set
Top 1%
0.9%
20
Cancer Research
116 papers in training set
Top 3%
0.8%
21
Cell Cycle
14 papers in training set
Top 0.3%
0.8%
22
Aging
69 papers in training set
Top 3%
0.8%
23
Nucleic Acids Research
1128 papers in training set
Top 18%
0.8%
24
Journal of Clinical Medicine
91 papers in training set
Top 7%
0.7%
25
Neoplasia
22 papers in training set
Top 0.7%
0.7%
26
Cell Death & Disease
126 papers in training set
Top 3%
0.5%
27
Medicine
30 papers in training set
Top 3%
0.5%
28
Biomedicines
66 papers in training set
Top 4%
0.5%
29
Epigenetics
43 papers in training set
Top 1%
0.5%
30
Frontiers in Physiology
93 papers in training set
Top 7%
0.5%